Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-α with AZT

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue 5, 1998, Pages 426-434

  Biswas, Debajit K ^a,c   Mhashilkar, Abner M ^a   Ewaniuk, Darren S ^a   Pezza, John A ^a   Oh, Lynette M ^b   Kamali Kannangara, Gallage S ^b   Tius, Marcus A ^b   Pardee, Arthur B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cellular; Combination therapy; Factors; TNF inhibitor; Viral

Indexed keywords

ANTIRETROVIRUS AGENT; CANVENTOL; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LYMPHOCYTE CULTURE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032529222     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199808150-00003     Document Type: Article

References (32)

1. Larder BA. Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10: S28-33.
2. St. Clair MH, Pennington KN, Rooney J, Barry DW. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the inter-company collaboration protocol. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:583-91.
3. Moutouh L, Corbeil J, Richman DD. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci USA 1996;93:6106-11.
4. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
5. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
6. Gallo RC. Mechanism of disease induction by HIV. J Acquir Immune Defic Syndr 1990;3:380-9.
7. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB. Cooperative inhibition of NF-κB and Tat-induced superactivation of human immunodeficiency virus type-1 long terminal repeat. Proc Natl Acad Sci USA 1993;90:11044-8.
8. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB activation. J Acquir Immune Defic Syndr 1993;6:778-86.
9. Berkhout B, Jeang K-T. Functional roles for the Tat promoter and enhancers in basal and Tat-induced expression of human immunodeficiency virus type 1 long terminal repeat. J Virol 1992;66: 139-49.
10. Cullen BR. Trans-activation of human immunodeficiency virus occurs via a bimodel mechanism. Cell 1986;46:973-82.
11. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992;56:375-94.
12. Biswas DK, Salas TR, Wang F, Ahlers CM, Dezube BJ, Pardee AB. A Tat-induced auto-upregulatory loop for superactivation of the human immunodeficiency virus type-1 promoter. J Virol 1995; 69:7437-44.
13. Buonagro L, Barillari G, Chang HK, et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992;66:7159-67.
14. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4.
15. Poli G, Fauci A. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-73.
16. Graziosi C, Gantt KR, Vaccarezza M, et al. Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc Natl Acad Sci USA 1996;93:4386-91.
17. Dezube BJ, Pardee AB, Chapman B, et al. Cytokine disregulation in AIDS: the in vivo over-expression of mRNA of tumor necrosis factor-α and its correlation with that of inflammatory cytokine GRO. J Acquir Immune Defic Syndr 1992;5:1099-1104.
18. Biswas DK, Tius M, Zhuo J, Pardee AB. Canventol inhibits HIV-1 replication by a Tat-induced Tar-independent mechanism. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:120-7.
19. Komori A, Yatsunami J, Suganuma M, et al. Anti-tumor promoting activity of Canventol and its synthetic analogs through inhibition of protein isoprenylation. Jpn J Cancer Res 1996;87:875-81.
20. Suganuma M, Okabe S, Sueoka E, et al. A new process of cancer prevention mediated through inhibition of tumor necrosis factor α expression. Cancer Res 1996;56:3711-15.
21. Bazzoni F, Kuys V, Shakov A, Jongeneel CV, Beutler B. Analysis of tumor necrosis factor promoter responses to ultraviolet light. J Clin Invest 199;93:56-62.
22. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Heiland DG, Marasco WA. Inhibition of HIV-1 Tat mediated LTR transactivation and HIV-1 infection by anti-Tat single-chain antibodies. EMBO J 1995;14:1542-51.
23. Mhashilkar AM, Biswas DK, Lavecchio J, Pardee AB, Marasco WA. Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-κB antagonists. J Virol 1997;71:6486-94.
24. Bagasara O, Khalili K, Seshamma T, Taylor JP, Pomerantz RJ. Tar-independent replication of human immunodeficiency virus type 1 in glial cells. J Virol 1992;66:7522-8.
25. Harrich D, Garcia J, Mitsuyasu R, Gaynor R. Tar-independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes. EMBO J 1990;9:4417-23.
26. Taylor JP, Pomerantz R, Bagasra O, et al. Tar-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation. EMBO J 1992;11:3395-405.
27. Angel P, Imagawa M, Chui R, et al. Phorbol ester inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987;49:729-39.
28. Bachelerie F, Alcami J, Arenzana-Seisdedos F, Virelizer JL. HIV enhancer activity perpetuated by NF-κB on infection of monocytes. Nature 1991;350:709-12.
29. Folgueira L, Algeciras A, MacMorran WS, Bren GD, Paya CV. The Ras-Raf pathway is activated in human immunodeficiency virus infected monocytes and participates in the activation of NF-κB. J Virol 1996;70:2332-8.
30. McElhinny JA, Macmorran WS, Bren GD, Ten RM, Israel A, Paya CV. Regulation of I kappa B alpha and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus. J Virol 1995;69:1500-9.
31. Paya CV, Ten RM, Bessia C, Alcami J, Hay RT, Virelizier JL. NF-κB-dependent induction of the NF-kappa B p50 subunit gene promoter underlies self-perpetuation of human immunodeficiency virus transcription in monocytic cells. Proc Natl Acad Sci USA 1992;89:7826-30.
32. Dezube BJ. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994;18:285-7.